AnaptysBio (NASDAQ:ANAB) Hits New 12-Month High at $37.50

AnaptysBio, Inc. (NASDAQ:ANAB)’s stock price hit a new 52-week high on Wednesday . The company traded as high as $37.50 and last traded at $36.79, with a volume of 13370 shares traded. The stock had previously closed at $36.96.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ANAB. Wells Fargo & Company began coverage on shares of AnaptysBio in a research report on Thursday, April 11th. They set an “overweight” rating and a $56.00 target price for the company. JPMorgan Chase & Co. upgraded shares of AnaptysBio from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $29.00 to $69.00 in a research report on Friday, July 19th. Leerink Partnrs reiterated an “outperform” rating on shares of AnaptysBio in a research report on Tuesday, April 16th. SVB Leerink initiated coverage on shares of AnaptysBio in a research report on Tuesday, April 16th. They set an “outperform” rating and a $47.00 price objective for the company. Finally, HC Wainwright initiated coverage on shares of AnaptysBio in a research report on Monday. They set a “buy” rating and a $55.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $51.89.

AnaptysBio Stock Down 0.0 %

The company’s fifty day moving average price is $25.97 and its 200-day moving average price is $24.27.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($1.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.10). The firm had revenue of $7.18 million during the quarter, compared to the consensus estimate of $4.55 million. AnaptysBio had a negative return on equity of 161.40% and a negative net margin of 711.17%. On average, research analysts expect that AnaptysBio, Inc. will post -6.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $35.00, for a total value of $52,500.00. Following the transaction, the insider now owns 11,618 shares of the company’s stock, valued at approximately $406,630. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Hollings Renton sold 1,950 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $23.16, for a total value of $45,162.00. Following the transaction, the director now owns 1,950 shares of the company’s stock, valued at approximately $45,162. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $35.00, for a total transaction of $52,500.00. Following the transaction, the insider now directly owns 11,618 shares in the company, valued at approximately $406,630. The disclosure for this sale can be found here. Insiders have sold 16,900 shares of company stock valued at $484,824 in the last 90 days. Company insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Great Point Partners LLC increased its position in AnaptysBio by 9.2% during the 4th quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock valued at $20,927,000 after purchasing an additional 82,648 shares during the period. Octagon Capital Advisors LP acquired a new stake in AnaptysBio in the 4th quarter worth approximately $2,570,000. Susquehanna Fundamental Investments LLC acquired a new stake in AnaptysBio in the 1st quarter worth approximately $1,221,000. First Light Asset Management LLC boosted its stake in AnaptysBio by 56.4% in the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after purchasing an additional 446,372 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in AnaptysBio by 22.7% in the 4th quarter. Franklin Resources Inc. now owns 405,115 shares of the biotechnology company’s stock worth $8,678,000 after purchasing an additional 75,025 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.